Polynovo Limited (ASX:PNV)

Mr Hoare was appointed a Director of PolyNovo on 27 January 2016. Mr Hoare is also Managing Director of Lohmann & Rauscher (Australia and New Zealand), a privately owned, multinational medical device company. Previously Mr Hoare was Managing Director of Smith & Nephew (Australia/NZ) until the end of 2015, one of Smith & Nephew’s largest global subsidiaries outside the US. He served as President of Smith & Nephew’s Asia-Pacific Advanced Wound Management (AWM) business for five years and was a member of the Global Executive Management for the AWM Division. In his 24 years with Smith & Nephew, he also held roles in marketing, divisional and general management. Mr Hoare’s career also includes a senior role at Bristol-Myers Squibb in surgical products, and Vice Chair of Australia’s peak medical device body, Medical Technology Association of Australia. Mr Hoare is currently a Non-Executive Director of Medical Developments International Ltd (ASX: MVP).

Dr Elliott was appointed a Director of PolyNovo on 28 October 2019. Until recently, Dr Elliott was – Global Head, Strategic Portfolio Management at CSL Behring, a role that is responsible for governance oversight and business value delivery from a multi-billion-dollar capital expansion portfolio. Dr Elliott previously held Strategic Expansion and Quality Senior Director roles within CSL, was the Managing Director at IDT Australia and commenced her career at DBL Faulding. Dr Elliott has a proven track record in product development, clinical trials, regulatory affairs, audits, quality management, project management and operational strategy. Her worldwide experience in new facility delivery, production scale up, strategy, regulatory affairs and audit will be invaluable to PolyNovo as the company scales its operations globally. Dr Elliott is a member of the Audit and Risk Committee.

Ms Emmanuel-Donnelly is an accomplished IP and business development professional with more than 30 years’ local and international experience. Ms Emmanuel-Donnelly has a Bachelor of Science with a major in Economics (Hons: Chem) from Monash University, Certificate in Intellectual Property Law from Queen Mary College, University of London, Masters of Enterprise from Melbourne University. She is a member of the Chartered Institute of Patent Attorneys UK and has been on the Board of the Institute of Patent and Trade Mark Attorneys of Australia for over a decade. Ms Emmanuel-Donnelly is currently on the Board of Medical Developments International Ltd and was previously Executive Manager of Business Development and Commercial at the CSIRO, having founded and grown the central IP management team and led the management of CSIRO’s IP portfolio for over 10 years and managed the growth of the CSIRO equity portfolio for 5 years. Previously she was in-house IP Counsel for Unilever in the UK and practised as a patent and trademark attorney for Wilson Gunn (UK) and Davies Collison Cave and Griffith Hack in Melbourne.

Mr Lumsden was appointed a Director of PolyNovo on 4 June 2021. He is an accomplished Chartered Accountant and finance executive with more than 20 years’ experience locally and internationally. He holds a Master of Arts in Accountancy and Finance (First Class Hons), is an Associate of The Chartered Governance Institute and a member of the Australian Institute of Company Directors. Mr Lumsden is currently Global Chief Operating Officer of Wellcom Group Pty Ltd (formerly Wellcom Group Limited) having previously held the roles of Chief Financial Officer and Company Secretary. Prior to joining Wellcom, Mr Lumsden was a Senior Manager within the Audit and Assurance practice of PricewaterhouseCoopers.

Mr. Douglas is an Australian and U.S. dual citizen, living in San Diego, but has a residence and family in Sydney.

Mr. Douglas has more than thirty-five years of experience in medical device technology, specialising in digital health. He also has a decade of experience in public company governance, including audit, risk management, and compliance oversight.

Mr. Douglas had a number of strategy and operational roles before joining ResMed Inc. Australia (NYSE: RMD, ASX: RMD) in 2001. Since then, he has had various roles in the U.S. and Australia including Vice President Corporate Marketing, Vice President Operations and President and Chief Operating Officer from 2013 to 2023. ResMed is a global medical device and software applications company providing solutions to diagnose, treat and manage respiratory disorders and improve care in out-of-hospital settings.

Mr. Douglas is currently a member of the Board of Directors and Audit Committee for Globus Medical Inc. (NYSE: GMED),a global musculoskeletal medical technology company.

Mr. Douglas holds a Master of Business Administration from Macquarie University, a Bachelor of Electrical Engineering with First Class Honors, and a Bachelor of Science in Computer Sciences from the University of New South Wales, Australia. He is also a Director Certified Member of the National Association ofCorporate Directors in the U.S.